BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
SAN DIEGO, Jan. 27, 2016 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, Chief Executive Officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 3:30 p.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and archived for replay through Tuesday, May 10, 2016.
About Retrophin
Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam®, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), nephrotic syndrome and others. For additional information, please visit www.retrophin.com.
Contact: Chris Cline, CFA Director, Investor Relations 646-564-3680 [email protected]
